Zobrazeno 1 - 10
of 424
pro vyhledávání: '"Abrocitinib"'
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 1793-1797 (2024)
Jingyao Liang,1,2,* Wei Li,1,2,* Wenyan Liu,1,2 Yihui Yu,1,2 Hui Ye,1,2 Xibao Zhang1,2 1Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People’s Republic of China; 2Department of Dermatology, Guangzhou
Externí odkaz:
https://doaj.org/article/2477356864184bfda4bb0e0a766af130
Autor:
Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Michael J. Cork, Lawrence F. Eichenfield, Eric L. Simpson, Athanasios Tsianakas, Urs Kerkmann, Claire Feeney, William Romero
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2285-2296 (2024)
Abstract Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3
Externí odkaz:
https://doaj.org/article/9fab2eaae3014f6bb0a226938e458120
Autor:
Siddhartha Sood, HBSc, Ahmed Bagit, BSc, Martin Heung, Khalad Maliyar, MD, Abrahim Abduelmula, MD, Muskaan Sachdeva, MD, Jorge R. Georgakopoulos, MD, Asfandyar Mufti, MD, Vimal H. Prajapati, MD, Jensen Yeung, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 31-33 (2024)
Externí odkaz:
https://doaj.org/article/e0075290e3ed47f1b40e5f9714c9489c
Autor:
April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1849-1861 (2024)
Abstract Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocit
Externí odkaz:
https://doaj.org/article/4fcba376017f4075bfd6d2381581d150
Autor:
Silvia Ferrucci, Maddalena Napolitano, Francesca Barei, Luca Valtellini, Angelo V. Marzano, Cataldo Patruno, Emanuela Martina, Anna Campanati
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 2, Pp 731-734 (2024)
Externí odkaz:
https://doaj.org/article/843525a4e52249cf9c7891143217bde6
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1389-1442 (2024)
Abstract Introduction Biological drugs (BD) and Janus kinase inhibitors (JAKi) have revolutionized the treatment of diverse dermatoses. However, there are concerns regarding their safety, especially the risk of cancer and opportunistic infections. He
Externí odkaz:
https://doaj.org/article/410903b1deb64e15bee541171f19a160
Autor:
Xiaoyu Xiong, MD, Rongyi Chen, MD, Liuyuan Wang, MD, Nanxuan Huang, MD, Lixia Huang, MD, Chunmei Wang, MD, Wujian Ke, MD
Publikováno v:
JAAD Case Reports, Vol 46, Iss , Pp 85-88 (2024)
Externí odkaz:
https://doaj.org/article/cdd6f6294b0443ad9e4aa6a421575e8e
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionConventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has ra
Externí odkaz:
https://doaj.org/article/d52280884dae4836bbd7f35c5b98e68b
Autor:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M. Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T. Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 919-932 (2024)
Abstract Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of p
Externí odkaz:
https://doaj.org/article/7023be759f84421298febcd280592b42
Publikováno v:
Advances in Dermatology and Allergology, Vol 41, Iss 1, Pp 72-77 (2024)
Externí odkaz:
https://doaj.org/article/cde79b9de20c46c79c368e5bf08b8bbd